Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) (PubMed:25561738). Part of chromatin remodeling machinery predominantly forms H3K4me1 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:17500065, PubMed:25561738). Acts as a coactivator for estrogen receptor by being recruited by ESR1, thereby activating transcription (PubMed:16603732)
Component of the MLL2 complex (also named ASCOM complex), at least composed of catalytic subunit KMT2D/MLL2, ASH2L, RBBP5, WDR5, NCOA6, DPY30, KDM6A, PAXIP1/PTIP, PAGR1 and alpha- and beta-tubulin (PubMed:12482968, PubMed:16603732, PubMed:17021013, PubMed:17500065, PubMed:17761849, PubMed:17851529, PubMed:23508102). Forms a core complex with the evolutionary conserved subcomplex WRAD composed of WDR5, RBBP5, ASH2L/ASH2 and DPY30 subunits; WRAD differentially stimulates the methyltransferase activity (PubMed:25561738). Interacts with ESR1; interaction is direct (PubMed:16603732).
Interacts (via WIN motif) with WDR5 (PubMed:22266653, PubMed:22665483)
Expressed in most adult tissues, including a variety of hematoipoietic cells, with the exception of the liver
LXXLL motifs 5 and 6 are essential for the association with ESR1 nuclear receptor
An autosomal dominant, congenital syndrome characterized by intellectual disability and additional features, including postnatal dwarfism, a peculiar facies characterized by long palpebral fissures with eversion of the lateral third of the lower eyelids, a broad and depressed nasal tip, large prominent earlobes, a cleft or high-arched palate, scoliosis, short fifth finger, persistence of fingerpads, radiographic abnormalities of the vertebrae, hands, and hip joints, and recurrent otitis media in infancy.
An autosomal dominant disorder characterized by choanal atresia, athelia or hypoplastic nipples, branchial sinus abnormalities, neck pits, lacrimal duct anomalies, hearing loss, external ear malformations, delayed or absent pubertal development, and thyroid abnormalities. Additional features may include developmental delay, growth failure and short stature.
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 1.61% |
| Lung Adenocarcinoma | 5.32% |
| Lung Small Cell Carcinoma | 10.68% |
| Lung Squamous Cell Carcinoma | 13.61% |
| Oesophagus Adenocarcinoma | 2.17% |
| Oesophagus Squamous Cell Carcinoma | 13.48% |
| Pancreas Ductal Carcinoma | 2.93% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to KMT2D, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 8
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03855631 | Kabuki Syndrome 1 | Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders | N/A | COMPLETED |
| NCT06475651 | Rare Fetal Genetic Diseases, Congenital Malformation | Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset | N/A | RECRUITING |